GSK Investigational Site
London, W1G 8HU, United Kingdom
NCT Number: NCT00517946
The purpose of this study is to establish whether MRI scanning is a sensitive measure of the effects of existing drug treatments on nasal dimensions following challenge with intranasal allergen in subjects with hayfever. If successful this technique could be applied to increase confidence for internal decision making and ultimately may be used to assess how effective a new drug treatment is.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Observational
London, W1G 8HU, United Kingdom
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: pseudoephedrine hydrochloride
Time frame: at 1hr post-dose and 30-60mins post-allergen challenge.
Time frame: At 1hr post-dose and 30-60mins post-allergen challenge
GlaxoSmithKline
Industry
An Investigation to Evaluate the Technique of MRI as an Assessment of the Effect of Anti-allergy Drug Treatment on Internal Nasal and Sinus Mucosal Anatomy Following Intranasal Allergen Challenge in Subjects With Seasonal Allergic Rhinitis.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05346718
Allergic Rhinitis, Birch Pollen Allergy
Hanover, Lower Saxony, Germany
View Trial DetailsNCT07052097
Hypersensitivity, Hypersensitivity, Immediate
Beijing, Beijing Municipality, China
View Trial DetailsNCT03369704
Hypersensitivity, Hypersensitivity, Immediate
Chiba, Japan
View Trial DetailsNCT06046391
Hypersensitivity, Hypersensitivity, Immediate
Beijing, Beijing Municipality, China
View Trial Details